More Progress For Novel PCSK9 Drug

–The PCSK9 synthesis inhibitor from The Medicines Company is getting close to phase 3 trials. More early information continues to accumulate about a novel cholesterol drug under development by The Medicines Company. The drug, which was initially created by Alnylam Pharmaceuticals, uses RNA interference technology to inhibit the synthesis of PCSK9 in the liver. The main...Click here to continue reading...

Source: CardioBrief - November 15, 2016 Category: Cardiology Authors: Larry Husten Tags: Prevention, Epidemiology & Outcomes Alnylam inclisiran PCSK9 PCSK9si The Medicines Company Source Type: blogs